Literature DB >> 10364321

Both neutralization resistance and high infectivity phenotypes are caused by mutations of interacting residues in the human immunodeficiency virus type 1 gp41 leucine zipper and the gp120 receptor- and coreceptor-binding domains.

E J Park1, G V Quinnan.   

Abstract

Neutralization resistance of human immunodeficiency virus type 1 (HIV-1) is a major impediment to vaccine development. We have found that residues of HIV-1 MN strain in the C terminus of gp120 and the leucine zipper (LZ) region of gp41 viral envelope proteins interact cooperatively to determine neutralization resistance and modulate infectivity. Further, results demonstrate that this interaction, by which regions of gp120 are assembled onto the LZ, involves amino acid residues intimately related to those which participate in the binding of the envelope to its receptor and coreceptor. Variations in this critical assembly structure determine the concordant, interdependent evolution of increased infectivity efficiency and neutralization resistance phenotypes of the envelopes. The results elucidate important structure-function relationships among epitopes that are important targets of vaccine development.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10364321      PMCID: PMC112630     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  39 in total

1.  Identification of individual human immunodeficiency virus type 1 gp120 amino acids important for CD4 receptor binding.

Authors:  U Olshevsky; E Helseth; C Furman; J Li; W Haseltine; J Sodroski
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

2.  Analysis of mutations in the V3 domain of gp160 that affect fusion and infectivity.

Authors:  K A Page; S M Stearns; D R Littman
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

3.  Atomic structure of a thermostable subdomain of HIV-1 gp41.

Authors:  K Tan; J Liu; J Wang; S Shen; M Lu
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-11       Impact factor: 11.205

4.  Retroviral envelope glycoproteins contain a "leucine zipper"-like repeat.

Authors:  E L Delwart; G Mosialos; T Gilmore
Journal:  AIDS Res Hum Retroviruses       Date:  1990-06       Impact factor: 2.205

5.  Another discontinuous epitope on glycoprotein gp120 that is important in human immunodeficiency virus type 1 neutralization is identified by a monoclonal antibody.

Authors:  D D Ho; M S Fung; Y Z Cao; X L Li; C Sun; T W Chang; N C Sun
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-15       Impact factor: 11.205

6.  Neutralization of divergent HIV-1 isolates by conformation-dependent human antibodies to Gp120.

Authors:  K S Steimer; C J Scandella; P V Skiles; N L Haigwood
Journal:  Science       Date:  1991-10-04       Impact factor: 47.728

7.  Lack of evidence for HIV-2 infection among at-risk individuals in Brazil.

Authors:  R M Hendry; D E Parks; D L Mello; G V Quinnan; B G Castro
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1991

8.  Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody.

Authors:  D D Ho; J A McKeating; X L Li; T Moudgil; E S Daar; N C Sun; J E Robinson
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

9.  Persistent productive HIV-1 infection of a CD4- human fetal thymocyte line.

Authors:  W C Hatch; K E Tanaka; T Calvelli; W K Rashbaum; Y Kress; W D Lyman
Journal:  J Immunol       Date:  1992-05-15       Impact factor: 5.422

10.  Mapping genetic determinants for human immunodeficiency virus type 1 resistance to soluble CD4.

Authors:  W A O'Brien; I S Chen; D D Ho; E S Daar
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

View more
  22 in total

1.  Evolution of two amino acid positions governing broad neutralization resistance in a strain of feline immunodeficiency virus over 7 years of persistence in cats.

Authors:  Mauro Pistello; Donatella Matteucci; Simone Giannecchini; Francesca Bonci; Olimpia Sichi; Silvano Presciuttini; Mauro Bendinelli
Journal:  Clin Diagn Lab Immunol       Date:  2003-11

2.  Direct evidence that C-peptide inhibitors of human immunodeficiency virus type 1 entry bind to the gp41 N-helical domain in receptor-activated viral envelope.

Authors:  Nicole R Kilgore; Karl Salzwedel; Mary Reddick; Graham P Allaway; Carl T Wild
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

3.  A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response.

Authors:  Peng Fei Zhang; Peter Bouma; Eun Ju Park; Joseph B Margolick; James E Robinson; Susan Zolla-Pazner; Michael N Flora; Gerald V Quinnan
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

4.  Concordant modulation of neutralization resistance and high infectivity of the primary human immunodeficiency virus type 1 MN strain and definition of a potential gp41 binding site in gp120.

Authors:  Maria Leavitt; Eun Ju Park; Igor A Sidorov; Dimiter S Dimitrov; Gerald V Quinnan
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

5.  Induction of neutralizing antibodies to Hendra and Nipah glycoproteins using a Venezuelan equine encephalitis virus in vivo expression system.

Authors:  Gabriel N Defang; Dimple Khetawat; Christopher C Broder; Gerald V Quinnan
Journal:  Vaccine       Date:  2010-11-02       Impact factor: 3.641

6.  Determinants of CD4 independence for a human immunodeficiency virus type 1 variant map outside regions required for coreceptor specificity.

Authors:  C C LaBranche; T L Hoffman; J Romano; B S Haggarty; T G Edwards; T J Matthews; R W Doms; J A Hoxie
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

7.  Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41.

Authors:  Cleo G Anastassopoulou; Thomas J Ketas; Per Johan Klasse; John P Moore
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-16       Impact factor: 11.205

8.  Mutations in gp120 contribute to the resistance of human immunodeficiency virus type 1 to membrane-anchored C-peptide maC46.

Authors:  Felix G Hermann; Lisa Egerer; Frances Brauer; Christian Gerum; Harald Schwalbe; Ursula Dietrich; Dorothee von Laer
Journal:  J Virol       Date:  2009-03-11       Impact factor: 5.103

9.  Envelope variants from women recently infected with clade A human immunodeficiency virus type 1 confer distinct phenotypes that are discerned by competition and neutralization experiments.

Authors:  Sally L Painter; Roman Biek; David C Holley; Mary Poss
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

10.  N-terminal substitutions in HIV-1 gp41 reduce the expression of non-trimeric envelope glycoproteins on the virus.

Authors:  Antu K Dey; Kathryn B David; Neelanjana Ray; Thomas J Ketas; Per J Klasse; Robert W Doms; John P Moore
Journal:  Virology       Date:  2007-11-26       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.